Page last updated: 2024-09-03

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and L-cycloserine

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with L-cycloserine in 2 studies

Compound Research Comparison

Studies
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Trials
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Recent Studies (post-2010)
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Studies
(L-cycloserine)
Trials
(L-cycloserine)
Recent Studies (post-2010) (L-cycloserine)
7911622015

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Other Studies

2 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and L-cycloserine

ArticleYear
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
    Bioorganic & medicinal chemistry, 2012, Nov-15, Volume: 20, Issue:22

    Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship

2012
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023